Catherine Friedman
Executive Venture Partner @ Google Ventures
Atherton, United States
Catherine Friedman is a Series B investor at Google Ventures in Atherton focused on Health Care and Medical. Catherine J. Friedman is based out of San Francisco, California and is the Executive Venture Partner of Google Ventures. Catherine previously worked at Morgan Stanley as a Managing Director. Catherine J. Friedman attended the University of Virginia’s Darden School of Business.
- Total investments:
- 13
- Last investment:
- Lead investor:
- 69%
Last updated:
For AI agents: llms.txt
Industries Catherine Friedman invests in
Stages Catherine Friedman invests in
Countries Catherine Friedman invests in
Investment Focus
Industry
- Health Care 7 (54%)
- Medical 4 (31%)
- Health Diagnostics 3 (23%)
- Women's 2 (15%)
- mHealth 2 (15%)
Stage
- Series B 6 (46%)
- Series A 5 (38%)
- Series D 1 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Contraline
|
Contraline is a medical device company that has developed a proprietary injectable hydrogel platform for use in reproductive and contraceptive applications. Contraline's first product, Adam, is implanted into the vas deferens through a minimally invasive, outpatient procedure and once implanted, the gel effectively blocks sperm. Adam isnon-hormonal, designed to last years, and easily reversible. | $92.5M / Series B / Jun 02, 2026 | |
Midi Health
|
Midi Health provides virtual healthcare services focused on midlife women’s health, especially around hormonal changes such as perimenopause and menopause, through personalized care plans delivered by clinicians trained in these areas. Its services include telehealth consultations that can integrate prescription support, supplements, lifestyleguidance, and symptom-specific treatments to address issues like weight, mood, sleep, and sexual wellness. Midi Health also offers tailored support protocols that consider an individual’s health history and goals to guide ongoing care. Its platform makes care accessible online and works with insurance for coverage of visits and prescriptions. The company additionally offers targeted supplements designed to complement its clinical care approach. | $100M / Series D / Feb 03, 2026 | |
Pelage Pharmaceuticals
|
Pelage Pharma delivers a clinically tested treatment for both men and women battling the emotional pain or social stigma of hair loss. Its non-invasive, topical small molecule drug platform activates hair follicle stem cells and stimulates robust hair growth. | $120M / Series B / Oct 15, 2025 | |
Vitara Biomedical
|
Vitara Biomedical has developed a therapeutic platform to support premature infants. Vitara Biomedical's platform was inspired by natural physiological processes to transform neonatal care. | $50M / Series B / Nov 18, 2024 | |
PeopleOne Health
|
PeopleOne Health provides world-class healthcare that seamlessly blends treatment and prevention, leading to significant savings for employers and employees by keeping people healthier. This is the next generation of value-based primary care. Employers save up to 30% on healthcare costs and enhance employee recruiting and retention. Employees getaccess to an award-winning health benefit at no cost, including a team of top-tier doctors and healthcare professionals. Leading employers and thousands of members trust PeopleOne Health and rate their customer satisfaction an excellent 90+ NPS (exceeding the healthcare industry average of 35). Discover more at peopleonehealth.com. | $32.3M / Series B / Oct 24, 2024 | |
|
Pelage Pharmaceuticals
|
Pelage Pharma delivers a clinically tested treatment for both men and women battling the emotional pain or social stigma of hair loss. Its non-invasive, topical small molecule drug platform activates hair follicle stem cells and stimulates robust hair growth. | $14M / Series A / Aug 13, 2024 | |
|
Midi Health
|
Midi Health provides virtual healthcare services focused on midlife women’s health, especially around hormonal changes such as perimenopause and menopause, through personalized care plans delivered by clinicians trained in these areas. Its services include telehealth consultations that can integrate prescription support, supplements, lifestyleguidance, and symptom-specific treatments to address issues like weight, mood, sleep, and sexual wellness. Midi Health also offers tailored support protocols that consider an individual’s health history and goals to guide ongoing care. Its platform makes care accessible online and works with insurance for coverage of visits and prescriptions. The company additionally offers targeted supplements designed to complement its clinical care approach. | $63M / Series B / Apr 24, 2024 | |
|
Pelage Pharmaceuticals
|
Pelage Pharma delivers a clinically tested treatment for both men and women battling the emotional pain or social stigma of hair loss. Its non-invasive, topical small molecule drug platform activates hair follicle stem cells and stimulates robust hair growth. | $16.8M / Series A / Feb 27, 2024 | |
Granata Bio
|
Granata Bio is a biotechnology focused on identifying and developing therapeutics for fertility patients. Founded in 2018, the Company recently announced a partnership with IBSA Institut Biochimique (Lugano CH) to co-develop a novel subcutaneous progesterone solution. | $14M / Series A / Jan 16, 2024 | |
|
Midi Health
|
Midi Health provides virtual healthcare services focused on midlife women’s health, especially around hormonal changes such as perimenopause and menopause, through personalized care plans delivered by clinicians trained in these areas. Its services include telehealth consultations that can integrate prescription support, supplements, lifestyleguidance, and symptom-specific treatments to address issues like weight, mood, sleep, and sexual wellness. Midi Health also offers tailored support protocols that consider an individual’s health history and goals to guide ongoing care. Its platform makes care accessible online and works with insurance for coverage of visits and prescriptions. The company additionally offers targeted supplements designed to complement its clinical care approach. | $25M / Series A / Sep 27, 2023 | |
| See all 13 investments → | |||
Co-Investors
About Google Ventures
Google Ventures invests in sectors including life sciences, consumer, enterprise, crypto, climate, and frontier technology. With Alphabet as its sole limited partner, Google Ventures focuses on long-term investments. Its operating partners assist startups in design, equity, diversity & inclusion, talent, and engineering and help them connectwith Google for technology and expertise. Founded in 2009 as Google Ventures, Google Ventures manages over $8 billion in assets with 400 active portfolio companies in North America and Europe. Some notable investments include Uber, Nest, Slack, GitLab, and One Medical. Google Ventures is based in the San Francisco Bay Area with offices in Cambridge, New York, and London.
Google Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Andy Wheeler
Partner
|
|||
Anika Gupta
Principal
|
|||
Anthony Philippakis
Venture Partner
|
|||
Ben Robbins
General Partner
|
|||
Bethany Tsui
Principal and Investor
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Catherine Friedman invest in?
Catherine Friedman invests primarily in Health Care, Medical and Health Diagnostics startups, most often at Series B and Series A stage. Most of the 13 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Catherine Friedman last invest?
The most recent investment recorded for Catherine Friedman closed in Jun 2026. Shizune tracks 13 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
